{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T08:52:35Z","timestamp":1789116755309,"version":"build-2803163510"},"reference-count":226,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Biological Macromolecules"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.ijbiomac.2026.150466","type":"journal-article","created":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T00:19:43Z","timestamp":1769127583000},"page":"150466","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"P1","title":["Recent advances in the analysis of the evolutionary RNA based therapeutics; a review"],"prefix":"10.1016","volume":"344","author":[{"given":"Hadeel A.","family":"Khalil","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nehal W.","family":"El-Sayed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rowan M.","family":"Elmoslhy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amira F.","family":"El-Yazbi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ijbiomac.2026.150466_bb0005","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1073\/pnas.75.1.280","article-title":"Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide","volume":"75","author":"Zamecnik","year":"1978","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"4","key":"10.1016\/j.ijbiomac.2026.150466_bb0010","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.cmet.2018.03.004","article-title":"RNA-targeted therapeutics","volume":"27","author":"Crooke","year":"2018","journal-title":"Cell Metab."},{"issue":"4","key":"10.1016\/j.ijbiomac.2026.150466_bb0015","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1039\/D0CS01261K","article-title":"Targeting RNA with small molecules: from fundamental principles towards the clinic","volume":"50","author":"Falese","year":"2021","journal-title":"Chem. Soc. Rev."},{"issue":"5\u20136","key":"10.1016\/j.ijbiomac.2026.150466_bb0020","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.cbpa.2009.08.003","article-title":"Identifying druggable disease-modifying gene products","volume":"13","author":"Dixon","year":"2009","journal-title":"Curr. Opin. Chem. Biol."},{"issue":"11","key":"10.1016\/j.ijbiomac.2026.150466_bb0025","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1002\/emmm.201202287","article-title":"Gene therapy on the move","volume":"5","author":"Kaufmann","year":"2013","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.ijbiomac.2026.150466_bb0030","series-title":"Progress in Molecular Biology and Translational Science","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/bs.pmbts.2023.12.016","article-title":"Chapter eight - advantages and disadvantages of RNA therapeutics","volume":"203","author":"Le Huy","year":"2024"},{"issue":"4","key":"10.1016\/j.ijbiomac.2026.150466_bb0035","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1089\/nat.2012.0350","article-title":"Uniqueness, advantages, challenges, solutions, and perspectives in therapeutics applying RNA nanotechnology","volume":"22","author":"Guo","year":"2012","journal-title":"Nucleic Acid Ther."},{"key":"10.1016\/j.ijbiomac.2026.150466_bb0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.slasd.2025.100254","article-title":"Off-target effects of oligonucleotides and approaches of preclinical assessments","volume":"35","author":"Ruan","year":"2025","journal-title":"SLAS Discovery"},{"issue":"4","key":"10.1016\/j.ijbiomac.2026.150466_bb0045","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1124\/pr.120.019554","article-title":"RNA drugs and RNA targets for small molecules: principles, progress, and challenges","volume":"72","author":"Yu","year":"2020","journal-title":"Pharmacol. Rev."},{"issue":"1","key":"10.1016\/j.ijbiomac.2026.150466_bb0050","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s43856-023-00419-1","article-title":"Possibilities and limitations of antisense oligonucleotide therapies for the treatment of monogenic disorders","volume":"4","author":"Lauffer","year":"2024","journal-title":"Commun. Med."},{"issue":"2","key":"10.1016\/j.ijbiomac.2026.150466_bb0055","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s40259-024-00644-7","article-title":"Splice-modulating antisense oligonucleotides as therapeutics for inherited metabolic diseases","volume":"38","author":"Chen","year":"2024","journal-title":"BioDrugs"},{"issue":"6","key":"10.1016\/j.ijbiomac.2026.150466_bb0060","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1038\/s41573-021-00162-z","article-title":"Antisense technology: an overview and prospectus","volume":"20","author":"Crooke","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"issue":"2","key":"10.1016\/j.ijbiomac.2026.150466_bb0065","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1042\/bj3120599","article-title":"Kinetic characteristics of Escherichia coli RNase H1: cleavage of various antisense oligonucleotide-RNA duplexes","volume":"312","author":"Crooke","year":"1995","journal-title":"Biochem. J."},{"key":"10.1016\/j.ijbiomac.2026.150466_bb0070","series-title":"Antisense Drug Technology: Principles, Strategies, and Applications","author":"Crooke","year":"2007"},{"key":"10.1016\/j.ijbiomac.2026.150466_bb0075","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1146\/annurev.pharmtox.010909.105654","article-title":"RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform","volume":"50","author":"Bennett","year":"2010","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.ijbiomac.2026.150466_bb0080","doi-asserted-by":"crossref","first-page":"255","DOI":"10.2165\/00003088-200241040-00002","article-title":"Fomivirsen: clinical pharmacology and potential drug interactions","volume":"41","author":"Geary","year":"2002","journal-title":"Clin. Pharmacokinet."},{"issue":"4","key":"10.1016\/j.ijbiomac.2026.150466_bb0085","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/S0002-9394(02)01325-9","article-title":"Fomivirsen for the treatment of cytomegalovirus retinitis1","volume":"133","author":"Jabs","year":"2002","journal-title":"Am. J. Ophthalmol."},{"issue":"4","key":"10.1016\/j.ijbiomac.2026.150466_bb0090","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/j.jacl.2016.04.013","article-title":"Long-term mipomersen treatment is associated with a reduction in cardiovascular events in patients with familial hypercholesterolemia","volume":"10","author":"Duell","year":"2016","journal-title":"J. Clin. Lipidol."},{"issue":"9","key":"10.1016\/j.ijbiomac.2026.150466_bb0095","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1161\/CIRCULATIONAHA.113.001292","article-title":"Lomitapide and mipomersen: two first-in-class drugs for reducing low-density lipoprotein cholesterol in patients with homozygous familial hypercholesterolemia","volume":"129","author":"Rader","year":"2014","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.ijbiomac.2026.150466_bb0100","doi-asserted-by":"crossref","DOI":"10.3909\/ricm0834","article-title":"Balancing low-density lipoprotein cholesterol reduction and hepatotoxicity with Lomitapide mesylate and Mipomersen in patients with homozygous familial hypercholesterolemia","volume":"18","author":"Won","year":"2017","journal-title":"Rev. Cardiovasc. Med."},{"issue":"2","key":"10.1016\/j.ijbiomac.2026.150466_bb0105","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1080\/14656566.2018.1550071","article-title":"Mipomersen and its use in familial hypercholesterolemia","volume":"20","author":"Parham","year":"2019","journal-title":"Expert. Opin. Pharmacother."},{"issue":"1","key":"10.1016\/j.ijbiomac.2026.150466_bb0110","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1002\/ehf2.13154","article-title":"Ligand conjugated antisense oligonucleotide for the treatment of transthyretin amyloidosis: preclinical and phase 1 data","volume":"8","author":"Viney","year":"2021","journal-title":"ESC Heart Failure"},{"issue":"9","key":"10.1016\/j.ijbiomac.2026.150466_bb0115","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1007\/s40265-024-02080-x","article-title":"Imetelstat: First Approval","volume":"84","author":"Keam","year":"2024","journal-title":"Drugs"},{"issue":"22","key":"10.1016\/j.ijbiomac.2026.150466_bb0120","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.3390\/cells13221869","article-title":"Clinical applications of antisense oligonucleotides in cancer: a focus on glioblastoma","volume":"13","author":"Khuu","year":"2024","journal-title":"Cells"},{"key":"10.1016\/j.ijbiomac.2026.150466_bb0125","first-page":"1","article-title":"Olezarsen: first approval","author":"Syed","year":"2025","journal-title":"Drugs"},{"issue":"7","key":"10.1016\/j.ijbiomac.2026.150466_bb0130","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1177\/0883073815627882","article-title":"Intrathecal injections in children with spinal muscular atrophy: nusinersen clinical trial experience","volume":"31","author":"Hach\u00e9","year":"2016","journal-title":"J. Child Neurol."},{"issue":"4","key":"10.1016\/j.ijbiomac.2026.150466_bb0135","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1038\/nn.4508","article-title":"Nusinersen, an antisense oligonucleotide drug for spinal muscular atrophy","volume":"20","author":"Corey","year":"2017","journal-title":"Nat. Neurosci."},{"issue":"2","key":"10.1016\/j.ijbiomac.2026.150466_bb0140","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1089\/nat.2017.0665","article-title":"FDA approval of nusinersen for spinal muscular atrophy makes 2016 the year of splice modulating oligonucleotides","volume":"27","author":"Aartsma-Rus","year":"2017","journal-title":"Nucleic Acid Ther."},{"issue":"1","key":"10.1016\/j.ijbiomac.2026.150466_bb0145","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1073\/pnas.98.1.42","article-title":"Antisense-induced exon skipping and synthesis of dystrophin in the mdx mouse","volume":"98","author":"Mann","year":"2001","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ijbiomac.2026.150466_bb0150","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.addr.2015.05.008","article-title":"Exon skipping therapy for Duchenne muscular dystrophy","volume":"87","author":"Kole","year":"2015","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"2","key":"10.1016\/j.ijbiomac.2026.150466_bb0155","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1002\/ana.24555","article-title":"Longitudinal effect of eteplirsen versus historical control on ambulation in Duchenne muscular dystrophy","volume":"79","author":"Mendell","year":"2016","journal-title":"Ann. Neurol."},{"issue":"5","key":"10.1016\/j.ijbiomac.2026.150466_bb0160","doi-asserted-by":"crossref","DOI":"10.1136\/jme-2023-109729","article-title":"Understanding individualised genetic interventions as research-treatment hybrids","volume":"51","author":"Johnston","year":"2024","journal-title":"J. Med. Ethics"},{"issue":"3","key":"10.1016\/j.ijbiomac.2026.150466_bb0165","first-page":"241","article-title":"Drug discovery perspectives of antisense oligonucleotides","volume":"31","author":"Kim","year":"2023"},{"issue":"6","key":"10.1016\/j.ijbiomac.2026.150466_bb0170","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/s41573-019-0017-4","article-title":"The current state and future directions of RNAi-based therapeutics","volume":"18","author":"Setten","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"issue":"4","key":"10.1016\/j.ijbiomac.2026.150466_bb0175","doi-asserted-by":"crossref","first-page":"279","DOI":"10.2307\/3869076","article-title":"Introduction of a chimeric chalcone synthase gene into petunia results in reversible co-suppression of homologous genes in trans","volume":"2","author":"Napoli","year":"1990","journal-title":"Plant Cell"},{"issue":"9","key":"10.1016\/j.ijbiomac.2026.150466_bb0180","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/nrg3978","article-title":"Knocking down disease: a progress report on siRNA therapeutics","volume":"16","author":"Wittrup","year":"2015","journal-title":"Nat. Rev. Genet."},{"issue":"1","key":"10.1016\/j.ijbiomac.2026.150466_bb0185","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1716153","article-title":"Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis","volume":"379","author":"Adams","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"24","key":"10.1016\/j.ijbiomac.2026.150466_bb0190","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1056\/NEJMoa1913147","article-title":"Phase 3 trial of RNAi therapeutic givosiran for acute intermittent porphyria","volume":"382","author":"Balwani","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"13","key":"10.1016\/j.ijbiomac.2026.150466_bb0195","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1056\/NEJMoa2021712","article-title":"Lumasiran, an RNAi therapeutic for primary hyperoxaluria type 1","volume":"384","author":"Garrelfs","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"16","key":"10.1016\/j.ijbiomac.2026.150466_bb0200","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1912387","article-title":"Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol","volume":"382","author":"Ray","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.ijbiomac.2026.150466_bb0205","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1080\/17460441.2024.2306843","article-title":"Vutrisiran: a new drug in the treatment landscape of hereditary transthyretin amyloid polyneuropathy","volume":"19","author":"Plant\u00e9-Bordeneuve","year":"2024","journal-title":"Expert Opin. Drug Discov."},{"issue":"18","key":"10.1016\/j.ijbiomac.2026.150466_bb0210","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1007\/s40265-023-01976-4","article-title":"Nedosiran: first approval","volume":"83","author":"Syed","year":"2023","journal-title":"Drugs"},{"issue":"2","key":"10.1016\/j.ijbiomac.2026.150466_bb0215","doi-asserted-by":"crossref","first-page":"131","DOI":"10.5582\/ddt.2025.01031","article-title":"Fitusiran: the first approved siRNA therapy for hemophilia via reducing plasma antithrombin levels","volume":"19","author":"Lu","year":"2025","journal-title":"Drug Discov. Ther."},{"key":"10.1016\/j.ijbiomac.2026.150466_bb0220","first-page":"1","article-title":"Fitusiran: first approval","author":"Lee","year":"2025","journal-title":"Drugs"},{"key":"10.1016\/j.ijbiomac.2026.150466_bb0225","doi-asserted-by":"crossref","DOI":"10.1016\/j.chroma.2024.465285","article-title":"Impact of mobile and stationary phases on siRNA duplex stability in liquid chromatography","volume":"1733","author":"Gilar","year":"2024","journal-title":"J. Chromatogr. A"},{"issue":"47","key":"10.1016\/j.ijbiomac.2026.150466_bb0230","doi-asserted-by":"crossref","first-page":"18590","DOI":"10.1021\/acs.analchem.4c05248","article-title":"Expanding the analytical toolbox for the nondenaturing analysis of siRNAs with salt-mediated ion-pair reversed-phase liquid chromatography","volume":"96","author":"Enmark","year":"2024","journal-title":"Anal. Chem."},{"key":"10.1016\/j.ijbiomac.2026.150466_bb0235","series-title":"A Study on Optimum Method Conditions for Denaturated and Non-Denaturated siRNA by Ion Pair Reversed-Phase Liquid Chromatography","author":"Rojahn","year":"2023"},{"key":"10.1016\/j.ijbiomac.2026.150466_bb0240","doi-asserted-by":"crossref","DOI":"10.1016\/j.chroma.2024.465552","article-title":"SEC x IP two-dimensional LCMS for the analysis of non-denatured and denatured cyclic-peptide siRNAs in a single step","volume":"1740","author":"Roussis","year":"2025","journal-title":"J. Chromatogr. A"},{"key":"10.1016\/j.ijbiomac.2026.150466_bb0245","doi-asserted-by":"crossref","first-page":"344431","DOI":"10.1016\/j.aca.2025.344431","article-title":"Identification of oligonucleotide drug impurities using heart-cutting two-dimensional liquid chromatography-tandem mass spectrometry (2D-LC-MS\/MS)","volume":"1371","author":"Zhou","year":"2025","journal-title":"Anal. Chim. Acta"},{"issue":"14","key":"10.1016\/j.ijbiomac.2026.150466_bb0250","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1080\/17576180.2025.2535953","article-title":"Development of an LC-MS\/MS assay to analyze a lipid-conjugated siRNA by solid phase extraction (SPE) in mouse plasma and tissue using a stable isotope labeled internal standard (SILIS)","volume":"17","author":"Sanford","year":"2025","journal-title":"Bioanalysis"},{"issue":"5","key":"10.1016\/j.ijbiomac.2026.150466_bb0255","doi-asserted-by":"crossref","first-page":"2736","DOI":"10.3390\/ijms23052736","article-title":"Current advances in RNA therapeutics for human diseases","volume":"23","author":"Zogg","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ijbiomac.2026.150466_bb0260","doi-asserted-by":"crossref","DOI":"10.1038\/mtna.2015.23","article-title":"SiRNA versus miRNA as therapeutics for gene silencing","volume":"4","author":"Lam","year":"2015","journal-title":"Mol. Ther.-Nucleic Acids"},{"issue":"3","key":"10.1016\/j.ijbiomac.2026.150466_bb0265","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.3390\/ijms25031469","article-title":"Trials and tribulations of MicroRNA therapeutics","volume":"25","author":"Seyhan","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"6055","key":"10.1016\/j.ijbiomac.2026.150466_bb0270","doi-asserted-by":"crossref","DOI":"10.1038\/319618a0","article-title":"Origin of life: the RNA world","volume":"319","author":"Gilbert","year":"1986","journal-title":"nature"},{"issue":"4949","key":"10.1016\/j.ijbiomac.2026.150466_bb0275","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1126\/science.1690918","article-title":"Direct gene transfer into mouse muscle in vivo","volume":"247","author":"Wolff","year":"1990","journal-title":"Science"},{"issue":"5047","key":"10.1016\/j.ijbiomac.2026.150466_bb0280","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1126\/science.1546298","article-title":"Reversal of diabetes insipidus in Brattleboro rats: intrahypothalamic injection of vasopressin mRNA","volume":"255","author":"Jirikowski","year":"1992","journal-title":"Science"},{"issue":"51","key":"10.1016\/j.ijbiomac.2026.150466_bb0285","doi-asserted-by":"crossref","first-page":"6610","DOI":"10.1016\/j.vaccine.2016.04.060","article-title":"Unique safety issues associated with virus-vectored vaccines: potential for and theoretical consequences of recombination with wild type virus strains","volume":"34","author":"Condit","year":"2016","journal-title":"Vaccine"},{"issue":"5102","key":"10.1016\/j.ijbiomac.2026.150466_bb0290","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1126\/science.8456302","article-title":"Heterologous protection against influenza by injection of DNA encoding a viral protein","volume":"259","author":"Ulmer","year":"1993","journal-title":"Science"},{"issue":"4\u20136","key":"10.1016\/j.ijbiomac.2026.150466_bb0295","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1159\/000053993","article-title":"Plasmid DNA vaccines: investigation of integration into host cellular DNA following intramuscular injection in mice","volume":"43","author":"Ledwith","year":"2000","journal-title":"Intervirology"},{"key":"10.1016\/j.ijbiomac.2026.150466_bb0300","series-title":"mRNA-Based Vaccine for COVID-19: They Are New But Not Unknown!","volume":"vol. 11, no. 3","author":"Chavda","year":"2023"},{"issue":"2","key":"10.1016\/j.ijbiomac.2026.150466_bb0305","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1177\/00185787241298140","article-title":"Respiratory syncytial virus vaccine (mRNA)","volume":"60","author":"Levien","year":"2025","journal-title":"Hosp. Pharm."},{"key":"10.1016\/j.ijbiomac.2026.150466_bb0310","doi-asserted-by":"crossref","DOI":"10.1016\/j.chroma.2025.465724","article-title":"Characterisation and analysis of mRNA critical quality attributes using liquid chromatography based methods","volume":"1745","author":"Webb","year":"2025","journal-title":"J. Chromatogr. A"},{"issue":"9","key":"10.1016\/j.ijbiomac.2026.150466_bb0315","doi-asserted-by":"crossref","first-page":"3886","DOI":"10.1021\/acs.analchem.3c05539","article-title":"Comprehensive impurity profiling of mRNA: evaluating current technologies and advanced analytical techniques","volume":"96","author":"Camperi","year":"2024","journal-title":"Anal. Chem."},{"issue":"2","key":"10.1016\/j.ijbiomac.2026.150466_bb0320","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtn.2025.102549","article-title":"Removal of dsRNA byproducts using affinity chromatography","volume":"36","author":"Clark","year":"2025","journal-title":"Mol. Ther. Nucleic Acids"},{"issue":"23","key":"10.1016\/j.ijbiomac.2026.150466_bb0325","doi-asserted-by":"crossref","first-page":"4229","DOI":"10.3390\/molecules24234229","article-title":"Aptamers: a review of their chemical properties and modifications for therapeutic application","volume":"24","author":"Adachi","year":"2019","journal-title":"Molecules"},{"issue":"4","key":"10.1016\/j.ijbiomac.2026.150466_bb0330","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1038\/sj.gt.3302900","article-title":"Gene therapy progress and prospects: RNA aptamers","volume":"14","author":"Que-Gewirth","year":"2007","journal-title":"Gene Ther."},{"key":"10.1016\/j.ijbiomac.2026.150466_bb0335","doi-asserted-by":"crossref","first-page":"6742","DOI":"10.3390\/ijms25126742","article-title":"Therapeutic applications of aptamers","volume":"25","author":"Santarpia","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.ijbiomac.2026.150466_bb0340","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1146\/annurev-pharmtox-010716-104558","article-title":"Aptamers as therapeutics","volume":"57","author":"Nimjee","year":"2017","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"issue":"15","key":"10.1016\/j.ijbiomac.2026.150466_bb0345","doi-asserted-by":"crossref","first-page":"7753","DOI":"10.1093\/nar\/gkz638","article-title":"Systems biology-based investigation of cooperating microRNAs as monotherapy or adjuvant therapy in cancer","volume":"47","author":"Lai","year":"2019","journal-title":"Nucleic Acids Res."},{"issue":"6","key":"10.1016\/j.ijbiomac.2026.150466_bb0350","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.tig.2022.02.006","article-title":"Emerging concepts of miRNA therapeutics: from cells to clinic","volume":"38","author":"Diener","year":"2022","journal-title":"Trends Genet."},{"key":"10.1016\/j.ijbiomac.2026.150466_bb0355","doi-asserted-by":"crossref","DOI":"10.1016\/j.slasd.2025.100254","article-title":"Off-target effects of oligonucleotides and approaches of preclinical assessments","volume":"35","author":"Ruan","year":"2025","journal-title":"SLAS Discovery"},{"issue":"3","key":"10.1016\/j.ijbiomac.2026.150466_bb0360","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/nrd.2016.246","article-title":"MicroRNA therapeutics: towards a new era for the management of cancer and other diseases","volume":"16","author":"Rupaimoole","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"issue":"4","key":"10.1016\/j.ijbiomac.2026.150466_bb0365","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1089\/nat.2012.0350","article-title":"Uniqueness, advantages, challenges, solutions, and perspectives in therapeutics applying RNA nanotechnology","volume":"22","author":"Guo","year":"2012","journal-title":"Nucleic Acid Ther."},{"issue":"2","key":"10.1016\/j.ijbiomac.2026.150466_bb0370","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.ymthe.2020.11.008","article-title":"Pharmacokinetics and proceedings in clinical application of nucleic acid therapeutics","volume":"29","author":"Herkt","year":"2021","journal-title":"Mol. Ther."},{"issue":"1","key":"10.1016\/j.ijbiomac.2026.150466_bb0375","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/bdd.2338","article-title":"Biodistribution and delivery of oligonucleotide therapeutics to the central nervous system: advances, challenges, and future perspectives","volume":"44","author":"Goto","year":"2023","journal-title":"Biopharm. Drug Dispos."},{"issue":"5","key":"10.1016\/j.ijbiomac.2026.150466_bb0380","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.3390\/biomedicines11051275","article-title":"RNA therapeutics: a healthcare paradigm shift","volume":"11","author":"Niazi","year":"2023","journal-title":"Biomedicines"},{"issue":"6","key":"10.1016\/j.ijbiomac.2026.150466_bb0385","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1089\/nat.2017.0691","article-title":"Impurities in oligonucleotide drug substances and drug products","volume":"27","author":"Capaldi","year":"2017","journal-title":"Nucleic Acid Ther."},{"issue":"2","key":"10.1016\/j.ijbiomac.2026.150466_bb0390","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1002\/mas.21615","article-title":"Therapeutic oligonucleotides, impurities, degradants, and their characterization by mass spectrometry","volume":"40","author":"Pourshahian","year":"2021","journal-title":"Mass Spectrom. Rev."},{"key":"10.1016\/j.ijbiomac.2026.150466_bb0395","doi-asserted-by":"crossref","DOI":"10.1016\/j.chroma.2025.465915","article-title":"Improving the chromatographic separation of phosphorothioate oligonucleotide from impurities by optimizing selectivity through mobile-phase conditions in ion-pair reversed-phase high-performance liquid chromatography","volume":"1750","author":"Obata","year":"2025","journal-title":"J. Chromatogr. A"},{"key":"10.1016\/j.ijbiomac.2026.150466_bb0400","first-page":"34","article-title":"Quantitation of a low level coeluting impurity present in a modified oligonucleotide by both LC\u2013MS and NMR","volume":"118","author":"Smith","year":"2016"},{"issue":"10","key":"10.1016\/j.ijbiomac.2026.150466_bb0405","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.4155\/bio.11.66","article-title":"Advantages of ion-exchange chromatography for oligonucleotide analysis","volume":"3","author":"Cook","year":"2011","journal-title":"Bioanalysis"},{"key":"10.1016\/j.ijbiomac.2026.150466_bb0410","doi-asserted-by":"crossref","DOI":"10.1016\/j.trac.2024.117758","article-title":"Recent advances and current challenges in hydrophilic interaction chromatography for the analysis of therapeutic oligonucleotides","volume":"176","author":"Lardeux","year":"2024","journal-title":"TrAC Trends Anal. Chem."},{"issue":"29","key":"10.1016\/j.ijbiomac.2026.150466_bb0415","doi-asserted-by":"crossref","first-page":"15717","DOI":"10.1021\/acs.analchem.5c01407","article-title":"Ion-pairing hydrophilic interaction chromatography for impurity profiling of therapeutic phosphorothioated oligonucleotides","volume":"97","author":"Tuti\u0161","year":"2025","journal-title":"Anal. Chem."},{"issue":"1","key":"10.1016\/j.ijbiomac.2026.150466_bb0420","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.ab.2011.02.040","article-title":"Characterization of side reactions during the annealing of small interfering RNAs","volume":"414","author":"Seiffert","year":"2011","journal-title":"Anal. Biochem."},{"key":"10.1016\/j.ijbiomac.2026.150466_bb0425","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.jpba.2016.12.036","article-title":"Evaluation of size-exclusion chromatography for the analysis of phosphorothioate oligonucleotides","volume":"136","author":"Shimoyama","year":"2017","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.ijbiomac.2026.150466_bb0430","first-page":"11","article-title":"Consideration for impurities contained in oligonucleotide therapeutics","volume":"51","author":"Sekiguchi","year":"2020"},{"issue":"23","key":"10.1016\/j.ijbiomac.2026.150466_bb0435","doi-asserted-by":"crossref","first-page":"5083","DOI":"10.1039\/D3TB00308F","article-title":"Next-generation materials for RNA\u2013lipid nanoparticles: lyophilization and targeted transfection","volume":"11","author":"Wang","year":"2023","journal-title":"J. Mater. Chem. B"},{"issue":"1","key":"10.1016\/j.ijbiomac.2026.150466_bb0440","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1038\/s41467-023-35803-x","article-title":"Uncovering the mechanism for aggregation in repeat expanded RNA reveals a reentrant transition","volume":"14","author":"Kimchi","year":"2023","journal-title":"Nat. Commun."},{"issue":"11","key":"10.1016\/j.ijbiomac.2026.150466_bb0445","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics14112357","article-title":"Stability study of mRNA-lipid nanoparticles exposed to various conditions based on the evaluation between physicochemical properties and their relation with protein expression ability","volume":"14","author":"Kamiya","year":"2022","journal-title":"Pharmaceutics"},{"issue":"4","key":"10.1016\/j.ijbiomac.2026.150466_bb0450","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.202013243","article-title":"Delivery of oligonucleotide-based therapeutics: challenges and opportunities","volume":"13","author":"Hammond","year":"2021","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.ijbiomac.2026.150466_bb0455","doi-asserted-by":"crossref","DOI":"10.1016\/j.biologicals.2024.101799","article-title":"Advances in mRNA vaccine research in the field of quality control","volume":"88","author":"Huang","year":"2024","journal-title":"Biologicals"},{"issue":"1","key":"10.1016\/j.ijbiomac.2026.150466_bb0460","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1089\/nat.2023.0021","article-title":"Report of the European medicines agency conference on RNA-based medicines","volume":"34","author":"Ehmann","year":"2024","journal-title":"Nucleic Acid Ther."},{"issue":"6","key":"10.1016\/j.ijbiomac.2026.150466_bb0465","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1038\/s12276-024-01267-2","article-title":"Regulatory RNA: from molecular insights to therapeutic frontiers","volume":"56","author":"Kim","year":"2024","journal-title":"Exp. Mol. Med."},{"issue":"1","key":"10.1016\/j.ijbiomac.2026.150466_bb0470","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1080\/14760584.2024.2354251","article-title":"Research progress on the quality control of mRNA vaccines","volume":"23","author":"Hu","year":"2024","journal-title":"Expert Rev. Vaccines"},{"key":"10.1016\/j.ijbiomac.2026.150466_bb0475","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcoa.2023.100079","article-title":"Separation of therapeutic oligonucleotides using ion-pair reversed-phase chromatography based on fundamental separation science","volume":"3","author":"Fornstedt","year":"2023","journal-title":"J. Chromatogr. Open"},{"issue":"1\u20132","key":"10.1016\/j.ijbiomac.2026.150466_bb0480","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S0021-9673(02)00306-0","article-title":"Ion-pair reversed-phase high-performance liquid chromatography analysis of oligonucleotides: retention prediction","volume":"958","author":"Gilar","year":"2002","journal-title":"J. Chromatogr. A"},{"issue":"2","key":"10.1016\/j.ijbiomac.2026.150466_bb0485","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.ab.2009.03.042","article-title":"Reversed-phase ion-pair liquid chromatography analysis and purification of small interfering RNA","volume":"390","author":"McCarthy","year":"2009","journal-title":"Anal. Biochem."},{"issue":"19","key":"10.1016\/j.ijbiomac.2026.150466_bb0490","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1016\/j.jchromb.2011.03.051","article-title":"Combining ion pairing agents for enhanced analysis of oligonucleotide therapeutics by reversed phase-ion pairing ultra performance liquid chromatography (UPLC)","volume":"879","author":"Levin","year":"2011","journal-title":"J. Chromatogr. B"},{"key":"10.1016\/j.ijbiomac.2026.150466_bb0495","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.talanta.2018.12.023","article-title":"Analysis of the first and second generation of antisense oligonucleotides in serum samples with the use of ultra high performance liquid chromatography coupled with tandem mass spectrometry","volume":"196","author":"Kaczmarkiewicz","year":"2019","journal-title":"Talanta"},{"issue":"2","key":"10.1016\/j.ijbiomac.2026.150466_bb0500","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.jchromb.2005.05.049","article-title":"Characterization and quantification of Bcl-2 antisense G3139 and metabolites in plasma and urine by ion-pair reversed phase HPLC coupled with electrospray ion-trap mass spectrometry","volume":"825","author":"Dai","year":"2005","journal-title":"J. Chromatogr. B"},{"key":"10.1016\/j.ijbiomac.2026.150466_bb0505","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.jchromb.2011.09.007","article-title":"Chromatographic methods for the determination of therapeutic oligonucleotides","volume":"883-884","author":"McGinnis","year":"2012","journal-title":"J. Chromatogr. B"},{"issue":"2","key":"10.1016\/j.ijbiomac.2026.150466_bb0510","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1006\/abio.1993.1340","article-title":"High-resolution liquid chromatography of oligonucleotides on nonporous alkylated styrene-divinylbenzene copolymers","volume":"212","author":"Huber","year":"1993","journal-title":"Anal. Biochem."},{"issue":"4","key":"10.1016\/j.ijbiomac.2026.150466_bb0515","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1089\/154545703322460612","article-title":"Characterization of therapeutic oligonucleotides using liquid chromatography with on-line mass spectrometry detection","volume":"13","author":"Gilar","year":"2003","journal-title":"Oligonucleotides"},{"key":"10.1016\/j.ijbiomac.2026.150466_bb0520","first-page":"65","article-title":"Reversed-phase ion-pair liquid chromatography electrospray ionization tandem mass spectrometry for separation, sequencing and mapping of sites of base modification of isomeric oligonucleotide adducts using monolithic column","volume":"1245","author":"Sharma","year":"2012"},{"issue":"7","key":"10.1016\/j.ijbiomac.2026.150466_bb0525","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1021\/ac960916h","article-title":"Analysis of oligonucleotides by HPLC\u2212electrospray ionization mass spectrometry","volume":"69","author":"Apffel","year":"1997","journal-title":"Anal. Chem."},{"issue":"17","key":"10.1016\/j.ijbiomac.2026.150466_bb0530","doi-asserted-by":"crossref","first-page":"3730","DOI":"10.1021\/ac990378j","article-title":"Analysis of nucleic acids by capillary ion-pair reversed-phase HPLC coupled to negative-ion electrospray ionization mass spectrometry","volume":"71","author":"Huber","year":"1999","journal-title":"Anal. Chem."},{"key":"10.1016\/j.ijbiomac.2026.150466_bb0535","article-title":"Effect of ion-pairing reagent hydrophobicity on liquid chromatography and mass spectrometry analysis of oligonucleotides","volume":"1666","author":"Donegan","year":"2022"},{"issue":"7","key":"10.1016\/j.ijbiomac.2026.150466_bb0540","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1021\/bi00600a020","article-title":"Studies on polynucleotides. 146. High-pressure liquid chromatography in polynucleotide synthesis","volume":"17","author":"Fritz","year":"1978","journal-title":"Biochemistry"},{"issue":"7","key":"10.1016\/j.ijbiomac.2026.150466_bb0545","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1002\/rcm.959","article-title":"Analysis of native and chemically modified oligonucleotides by tandem ion-pair reversed-phase high-performance liquid chromatography\/electrospray ionization mass spectrometry","volume":"17","author":"Fountain","year":"2003","journal-title":"Rapid Commun. Mass Spectrom."},{"issue":"21","key":"10.1016\/j.ijbiomac.2026.150466_bb0550","doi-asserted-by":"crossref","first-page":"5109","DOI":"10.1021\/ac010587f","article-title":"Analysis of polymerase chain reaction products by on-line liquid chromatography\u2212 mass spectrometry for genotyping of polymorphic short tandem repeat loci","volume":"73","author":"Oberacher","year":"2001","journal-title":"Anal. Chem."},{"issue":"2","key":"10.1016\/j.ijbiomac.2026.150466_bb0555","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1021\/ac0487395","article-title":"Analysis of biological and synthetic ribonucleic acids by liquid chromatography\u2212mass spectrometry using monolithic capillary columns","volume":"77","author":"H\u00f6lzl","year":"2005","journal-title":"Anal. Chem."},{"issue":"1\u20132","key":"10.1016\/j.ijbiomac.2026.150466_bb0560","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.jchromb.2006.03.008","article-title":"Liquid chromatography electrospray ionization mass spectrometry analysis of the ocular metabolites from a short interfering RNA duplex","volume":"835","author":"Beverly","year":"2006","journal-title":"J. Chromatogr. B"},{"issue":"6","key":"10.1016\/j.ijbiomac.2026.150466_bb0565","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1002\/mas.10008","article-title":"Practical implications of some recent studies in electrospray ionization fundamentals","volume":"20","author":"Cech","year":"2001","journal-title":"Mass Spectrom. Rev."},{"issue":"2","key":"10.1016\/j.ijbiomac.2026.150466_bb0570","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/s13361-012-0509-5","article-title":"The effect of organic modifiers on electrospray ionization charge-state distribution and desorption efficiency for oligonucleotides","volume":"24","author":"Chen","year":"2013","journal-title":"J. Am. Soc. Mass Spectrom."},{"issue":"4","key":"10.1016\/j.ijbiomac.2026.150466_bb0575","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1002\/rcm.6773","article-title":"Comparing ion-pairing reagents and sample dissolution solvents for ion-pairing reversed-phase liquid chromatography\/electrospray ionization mass spectrometry analysis of oligonucleotides","volume":"28","author":"Gong","year":"2014","journal-title":"Rapid Commun. Mass Spectrom."},{"issue":"3","key":"10.1016\/j.ijbiomac.2026.150466_bb0580","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1080\/10408347.2018.1517034","article-title":"Analysis of antisense oligonucleotides and their metabolites with the use of ion pair reversed-phase liquid chromatography coupled with mass spectrometry","volume":"49","author":"Kaczmarkiewicz","year":"2019","journal-title":"Crit. Rev. Anal. Chem."},{"issue":"1","key":"10.1016\/j.ijbiomac.2026.150466_bb0585","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/1044-0305(94)00086-F","article-title":"Molecular mass measurement of intact ribonucleic acids via electrospray ionization quadrupole mass spectrometry","volume":"6","author":"Limbach","year":"1995","journal-title":"J. Am. Soc. Mass Spectrom."},{"key":"10.1016\/j.ijbiomac.2026.150466_bb0590","article-title":"Phosphorothioate oligonucleotides separation in ion-pairing reversed-phase liquid chromatography: effect of temperature","volume":"1681","author":"Kadlecov\u00e1","year":"2022"},{"key":"10.1016\/j.ijbiomac.2026.150466_bb0595","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcoa.2024.100200","article-title":"Weak to strong ion-pair gradients to expand the selectivity of oligonucleotide separations in reversed phase liquid chromatography - a proof of concept","volume":"7","author":"Fekete","year":"2025","journal-title":"J. Chromatogr. Open"},{"issue":"20","key":"10.1016\/j.ijbiomac.2026.150466_bb0600","first-page":"2912","article-title":"Influence of the pore size of reversed phase materials on peptide purification processes","volume":"1218","author":"G\u00e9taz","year":"2011"},{"issue":"1\u20132","key":"10.1016\/j.ijbiomac.2026.150466_bb0605","first-page":"201","article-title":"Characterization of some physical and chromatographic properties of monolithic poly (styrene\u2013co-divinylbenzene) columns","volume":"1030","author":"Oberacher","year":"2004"},{"key":"10.1016\/j.ijbiomac.2026.150466_bb0610","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.chroma.2019.02.026","article-title":"Small alkyl amines as ion-pair reagents for the separation of positional isomers of impurities in phosphate diester oligonucleotides","volume":"1594","author":"Roussis","year":"2019","journal-title":"J. Chromatogr. A"},{"issue":"2","key":"10.1016\/j.ijbiomac.2026.150466_bb0615","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s00216-019-02236-9","article-title":"Analytical and preparative separation of phosphorothioated oligonucleotides: columns and ion-pair reagents","volume":"412","author":"Enmark","year":"2020","journal-title":"Anal. Bioanal. Chem."},{"key":"10.1016\/j.ijbiomac.2026.150466_bb0620","doi-asserted-by":"crossref","DOI":"10.1016\/j.chroma.2020.461653","article-title":"Impact of stationary-phase pore size on chromatographic performance using oligonucleotide separation as a model","volume":"1634","author":"Bagge","year":"2020","journal-title":"J. Chromatogr. A"},{"issue":"24","key":"10.1016\/j.ijbiomac.2026.150466_bb0625","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.4155\/bio-2020-0225","article-title":"Development of a bioanalytical method for an antisense therapeutic using high-resolution mass spectrometry","volume":"12","author":"Sun","year":"2020","journal-title":"Bioanalysis"},{"issue":"23","key":"10.1016\/j.ijbiomac.2026.150466_bb0630","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.4155\/bio-2017-0145","article-title":"Quantitative analysis of imetelstat in plasma with LC-MS\/MS using solid-phase or hybridization extraction","volume":"9","author":"Dillen","year":"2017","journal-title":"Bioanalysis"},{"key":"10.1016\/j.ijbiomac.2026.150466_bb0635","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.jpba.2017.12.027","article-title":"Development and validation of a bioanalytical method for quantification of LNA-i-miR-221, a 13-mer oligonucleotide, in rat plasma using LC\u2013MS\/MS","volume":"150","author":"Franzoni","year":"2018","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.ijbiomac.2026.150466_bb0640","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1208\/s12248-012-9381-2","article-title":"Phosphorothioate oligonucleotide quantification by \u03bc-liquid chromatography-mass spectrometry","volume":"14","author":"Erb","year":"2012","journal-title":"AAPS J."},{"key":"10.1016\/j.ijbiomac.2026.150466_bb0645","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.omtn.2019.07.006","article-title":"Metabolite profiling of the antisense oligonucleotide eluforsen using liquid chromatography-mass spectrometry","volume":"17","author":"Kim","year":"2019","journal-title":"Mol. Ther.\u2013Nucleic Acids"},{"key":"10.1016\/j.ijbiomac.2026.150466_bb0650","doi-asserted-by":"crossref","first-page":"7453","DOI":"10.1007\/s00216-020-02878-0","article-title":"Studying in vitro metabolism of the first and second generation of antisense oligonucleotides with the use of ultra-high-performance liquid chromatography coupled with quadrupole time-of-flight mass spectrometry","volume":"412","author":"Kilanowska","year":"2020","journal-title":"Anal. Bioanal. Chem."},{"issue":"1","key":"10.1016\/j.ijbiomac.2026.150466_bb0655","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s10337-017-3380-5","article-title":"Advances on size exclusion chromatography and applications on the analysis of protein biopharmaceuticals and protein aggregates: a Mini review","volume":"81","author":"Brusotti","year":"2018","journal-title":"Chromatographia"},{"key":"10.1016\/j.ijbiomac.2026.150466_bb0660","doi-asserted-by":"crossref","DOI":"10.1016\/j.chroma.2024.464862","article-title":"Size exclusion chromatography of biopharmaceutical products: from current practices for proteins to emerging trends for viral vectors, nucleic acids and lipid nanoparticles","volume":"1722","author":"D\u2019Atri","year":"2024","journal-title":"J. Chromatogr. A"},{"issue":"33","key":"10.1016\/j.ijbiomac.2026.150466_bb0665","doi-asserted-by":"crossref","first-page":"5609","DOI":"10.1016\/j.chroma.2011.06.057","article-title":"Characterization of small interfering RNA by non-denaturing ion-pair reversed-phase liquid chromatography","volume":"1218","author":"Noll","year":"2011","journal-title":"J. Chromatogr. A"},{"issue":"1","key":"10.1016\/j.ijbiomac.2026.150466_bb0670","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.ab.2011.02.040","article-title":"Characterization of side reactions during the annealing of small interfering RNAs","volume":"414","author":"Seiffert","year":"2011","journal-title":"Anal. Biochem."},{"key":"10.1016\/j.ijbiomac.2026.150466_bb0675","doi-asserted-by":"crossref","DOI":"10.1016\/j.chroma.2024.464756","article-title":"Evaluation of size-exclusion chromatography, multi-angle light scattering detection and mass photometry for the characterization of mRNA","volume":"1719","author":"De Vos","year":"2024","journal-title":"J. Chromatogr. A"},{"issue":"20","key":"10.1016\/j.ijbiomac.2026.150466_bb0680","doi-asserted-by":"crossref","first-page":"4627","DOI":"10.1007\/s00216-025-05979-w","article-title":"Size-exclusion chromatography with post-column nucleic acid staining and fluorescence detection for sensitive ribonucleic acid analysis","volume":"417","author":"Hoevelmann","year":"2025","journal-title":"Anal. Bioanal. Chem."},{"key":"10.1016\/j.ijbiomac.2026.150466_bb0685","series-title":"Ion-Exchange Chromatography and Related Techniques","first-page":"387","article-title":"Chapter 19 - separation of oligonucleotides by ion-exchange chromatography","author":"Poole","year":"2024"},{"key":"10.1016\/j.ijbiomac.2026.150466_bb0690","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S0021-9673(00)85615-0","article-title":"Preparation of a porous microparticulatee anion-exchange chromatography support for proteins","volume":"185","author":"Alpert","year":"1979","journal-title":"J. Chromatogr. A"},{"key":"10.1016\/j.ijbiomac.2026.150466_bb0695","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S0076-6879(96)71009-1","article-title":"[7] High-resolution nucleic acid separations by high-performance liquid chromatography","volume":"271","author":"Thayer","year":"1996","journal-title":"Methods Enzymol."},{"key":"10.1016\/j.ijbiomac.2026.150466_bb0700","doi-asserted-by":"crossref","DOI":"10.1021\/op990091o","article-title":"Process development for purification of therapeutic antisense oligonucleotides by anion-exchange chromatography","volume":"4","author":"Deshmukh","year":"2000","journal-title":"Org. Process. Res. Dev."},{"issue":"1","key":"10.1016\/j.ijbiomac.2026.150466_bb0705","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.ab.2004.11.013","article-title":"Control of oligonucleotide retention on a pH-stabilized strong anion exchange column","volume":"338","author":"Thayer","year":"2005","journal-title":"Anal. Biochem."},{"issue":"7","key":"10.1016\/j.ijbiomac.2026.150466_bb0710","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1021\/acs.oprd.4c00013","article-title":"Oligonucleotide purification by ion exchange chromatography: a step-by-step guide to process understanding, modeling, and simulation","volume":"28","author":"Kobl","year":"2024","journal-title":"Org. Process. Res. Dev."},{"key":"10.1016\/j.ijbiomac.2026.150466_bb0715","doi-asserted-by":"crossref","DOI":"10.1016\/j.chroma.2024.465412","article-title":"Robustness evaluation of weak anion exchange chromatography method for the purity analysis of therapeutic oligonucleotides","volume":"1736","author":"Nercessian","year":"2024","journal-title":"J. Chromatogr. A"},{"key":"10.1016\/j.ijbiomac.2026.150466_bb0720","doi-asserted-by":"crossref","DOI":"10.1016\/j.chroma.2025.465790","article-title":"A comparative study of ion exchange vs. ion pair chromatography for preparative separation of oligonucleotides","volume":"1746","author":"Enmark","year":"2025","journal-title":"J. Chromatogr. A"},{"key":"10.1016\/j.ijbiomac.2026.150466_bb0725","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S0021-9673(00)96972-3","article-title":"Hydrophilic-interaction chromatography for the separation of peptides, nucleic acids and other polar compounds","volume":"499","author":"Alpert","year":"1990","journal-title":"J. Chromatogr. A"},{"key":"10.1016\/j.ijbiomac.2026.150466_bb0730","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.chroma.2019.02.016","article-title":"Oligonucleotide analysis by hydrophilic interaction liquid chromatography-mass spectrometry in the absence of ion-pair reagents","volume":"1595","author":"Lobue","year":"2019","journal-title":"J. Chromatogr. A"},{"issue":"24","key":"10.1016\/j.ijbiomac.2026.150466_bb0735","doi-asserted-by":"crossref","first-page":"15474","DOI":"10.3390\/ijms232415474","article-title":"Bioanalysis of oligonucleotide by LC\u2013MS: effects of ion pairing regents and recent advances in ion-pairing-free analytical strategies","volume":"23","author":"Liu","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ijbiomac.2026.150466_bb0740","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.jchromb.2016.11.001","article-title":"Application of hydrophilic interaction liquid chromatography coupled with mass spectrometry in the analysis of phosphorothioate oligonucleotides in serum","volume":"1040","author":"Studzi\u0144ska","year":"2017","journal-title":"J. Chromatogr. B"},{"issue":"12","key":"10.1016\/j.ijbiomac.2026.150466_bb0745","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.4155\/bio-2019-0031","article-title":"An oligonucleotide bioanalytical LC\u2013SRM methodology entirely liberated from ion-pairing","volume":"11","author":"MacNeill","year":"2019","journal-title":"Bioanalysis"},{"issue":"1","key":"10.1016\/j.ijbiomac.2026.150466_bb0750","doi-asserted-by":"crossref","first-page":"47","DOI":"10.4155\/bio-2021-0216","article-title":"Novel hydrophilic-phase extraction, HILIC and high-resolution MS quantification of an RNA oligonucleotide in plasma","volume":"14","author":"Anand","year":"2022","journal-title":"Bioanalysis"},{"key":"10.1016\/j.ijbiomac.2026.150466_bb0755","doi-asserted-by":"crossref","DOI":"10.1016\/j.chroma.2023.463785","article-title":"Comprehensive evaluation of zwitterionic hydrophilic liquid chromatography stationary phases for oligonucleotide characterization","volume":"1690","author":"Lardeux","year":"2023","journal-title":"J. Chromatogr. A"},{"issue":"32","key":"10.1016\/j.ijbiomac.2026.150466_bb0760","doi-asserted-by":"crossref","first-page":"5480","DOI":"10.1016\/j.chroma.2011.06.044","article-title":"Analysis of oligonucleotides by hydrophilic interaction liquid chromatography coupled to negative ion electrospray ionization mass spectrometry","volume":"1218","author":"Gong","year":"2011","journal-title":"J. Chromatogr. A"},{"key":"10.1016\/j.ijbiomac.2026.150466_bb0765","series-title":"Analysis of Long-Chain Oligo-DNA with the Shodex\u2122 VN-50 2D HILIC Column","author":"S. D. America","year":"2022"},{"key":"10.1016\/j.ijbiomac.2026.150466_bb0770","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2020.113105","article-title":"Characterization of therapeutic oligonucleotides by liquid chromatography","volume":"182","author":"Goyon","year":"2020","journal-title":"J. Pharm. Biomed. Anal."},{"issue":"8","key":"10.1016\/j.ijbiomac.2026.150466_bb0775","doi-asserted-by":"crossref","first-page":"5944","DOI":"10.1021\/acs.analchem.0c00114","volume":"92","author":"Goyon","year":"2020","journal-title":"Anal. Chem."},{"key":"10.1016\/j.ijbiomac.2026.150466_bb0780","doi-asserted-by":"crossref","DOI":"10.1016\/j.jchromb.2023.123812","article-title":"Optimization of orthogonal separations for the analysis of oligonucleotides using 2D-LC","volume":"1227","author":"Vanhinsbergh","year":"2023","journal-title":"J. Chromatogr. B"},{"key":"10.1016\/j.ijbiomac.2026.150466_bb0785","doi-asserted-by":"crossref","DOI":"10.1016\/j.chroma.2024.465076","article-title":"Two-dimensional sequential selective comprehensive chiral\u00d7reversed-phase liquid chromatography of synthetic phosphorothioate oligonucleotide diastereomers","volume":"1730","author":"Li","year":"2024","journal-title":"J. Chromatogr. A"},{"issue":"1","key":"10.1016\/j.ijbiomac.2026.150466_bb0790","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S0378-4347(96)00499-9","article-title":"Determination of antisense phosphorothioate oligonucleotides and catabolites in biological fluids and tissue extracts using anion-exchange high-performance liquid chromatography and capillary gel electrophoresis","volume":"692","author":"Chen","year":"1997","journal-title":"J. Chromatogr. B Biomed. Sci. Appl."},{"issue":"4","key":"10.1016\/j.ijbiomac.2026.150466_bb0795","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1002\/bmc.1696","article-title":"Determination of therapeutic oligonucleotides using capillary gel electrophoresis","volume":"26","author":"Chen","year":"2012","journal-title":"Biomed. Chromatogr."},{"issue":"16","key":"10.1016\/j.ijbiomac.2026.150466_bb0800","doi-asserted-by":"crossref","first-page":"3218","DOI":"10.1021\/ac970280+","article-title":"Quantitative determination of short single-stranded oligonucleotides from blood plasma using capillary electrophoresis with laser-induced fluorescence","volume":"69","author":"Reyderman","year":"1997","journal-title":"Anal. Chem."},{"key":"10.1016\/j.ijbiomac.2026.150466_bb0805","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.chroma.2012.03.070","article-title":"Determination of RNA degradation by capillary electrophoresis with cyan light-emitted diode-induced fluorescence","volume":"1239","author":"Yang","year":"2012","journal-title":"J. Chromatogr. A"},{"issue":"7","key":"10.1016\/j.ijbiomac.2026.150466_bb0810","first-page":"670","article-title":"Pharmacokinetics of an antisense oligonucleotide injected intravitreally in monkeys","volume":"26","author":"Leeds","year":"1998","journal-title":"Drug Metab. Dispos."},{"issue":"15","key":"10.1016\/j.ijbiomac.2026.150466_bb0815","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1021\/ac951179c","article-title":"Oligomeric separation of ionic and nonionic ethoxylated polymers by capillary gel electrophoresis","volume":"68","author":"Wallingford","year":"1996","journal-title":"Anal. Chem."},{"issue":"1","key":"10.1016\/j.ijbiomac.2026.150466_bb0820","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1002\/jssc.202000833","article-title":"Recent developments in the characterization of nucleic acids by liquid chromatography, capillary electrophoresis, ion mobility, and mass spectrometry (2010\u22122020)","volume":"44","author":"Santos","year":"2021","journal-title":"J. Sep. Sci."},{"key":"10.1016\/j.ijbiomac.2026.150466_bb0825","article-title":"Analytical factors for optimization of chain-length distribution analysis of mRNA using capillary gel electrophoresis","volume":"1754","author":"Yamamoto","year":"2025","journal-title":"J. Chromatogr. A"},{"key":"10.1016\/j.ijbiomac.2026.150466_bb0830","series-title":"Oligonucleotide Bioanalysis: Sensitivity Versus Specificity","first-page":"1299","volume":"vol. 3","author":"Wang","year":"2011"},{"key":"10.1016\/j.ijbiomac.2026.150466_bb0835","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2021.114368","article-title":"Recent advances in therapeutic nucleic acids and their analytical methods","volume":"206","author":"Talap","year":"2021","journal-title":"J. Pharm. Biomed. Anal."},{"issue":"9","key":"10.1016\/j.ijbiomac.2026.150466_bb0840","first-page":"1775","article-title":"Current state of oligonucleotide characterization using liquid chromatography-mass spectrometry: insight into critical issues","volume":"31","author":"Sutton","year":"2020"},{"issue":"15","key":"10.1016\/j.ijbiomac.2026.150466_bb0845","doi-asserted-by":"crossref","first-page":"10548","DOI":"10.1021\/acs.analchem.0c01382","article-title":"Hybridization liquid chromatography\u2013tandem mass spectrometry: an alternative bioanalytical method for antisense oligonucleotide quantitation in plasma and tissue samples","volume":"92","author":"Li","year":"2020","journal-title":"Anal. Chem."},{"key":"10.1016\/j.ijbiomac.2026.150466_bb0850","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.trsl.2021.11.009","article-title":"Development of mRNA manufacturing for vaccines and therapeutics: mRNA platform requirements and development of a scalable production process to support early phase clinical trials","volume":"242","author":"Whitley","year":"2022","journal-title":"Transl. Res."},{"key":"10.1016\/j.ijbiomac.2026.150466_bb0855","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.addr.2020.12.014","article-title":"Self-assembled mRNA vaccines","volume":"170","author":"Kim","year":"2021","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"16","key":"10.1016\/j.ijbiomac.2026.150466_bb0860","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1016\/j.vaccine.2021.03.038","article-title":"mRNA vaccines manufacturing: challenges and bottlenecks","volume":"39","author":"Rosa","year":"2021","journal-title":"Vaccine"},{"key":"10.1016\/j.ijbiomac.2026.150466_bb0865","doi-asserted-by":"crossref","DOI":"10.1016\/j.chroma.2023.464321","article-title":"Messenger RNA chromatographic purification: advances and challenges","volume":"1707","author":"Feng","year":"2023","journal-title":"J. Chromatogr. A"},{"issue":"38","key":"10.1016\/j.ijbiomac.2026.150466_bb0870","doi-asserted-by":"crossref","first-page":"14308","DOI":"10.1021\/acs.analchem.3c02552","article-title":"Liquid chromatography methods for analysis of mRNA poly(A) tail length and heterogeneity","volume":"95","author":"Gilar","year":"2023","journal-title":"Anal. Chem."},{"issue":"40","key":"10.1016\/j.ijbiomac.2026.150466_bb0875","first-page":"15017","article-title":"Separation of plasmid DNA topological forms, messenger RNA, and lipid nanoparticle aggregates using an ultrawide pore size exclusion chromatography column","volume":"95","author":"Goyon","year":"2023"},{"issue":"20","key":"10.1016\/j.ijbiomac.2026.150466_bb0880","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1016\/j.chroma.2011.03.008","article-title":"Influence of the pore size of reversed phase materials on peptide purification processes","volume":"1218","author":"Ayalew","year":"2011","journal-title":"J. Chromatogr. A"},{"issue":"11","key":"10.1016\/j.ijbiomac.2026.150466_bb0885","doi-asserted-by":"crossref","first-page":"6254","DOI":"10.3390\/ijms25116254","article-title":"Optimizing messenger RNA analysis using ultra-wide pore size exclusion chromatography columns","volume":"25","author":"D\u2019Atri","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ijbiomac.2026.150466_bb0890","series-title":"Manufacturing Methods for Production of RNA Transcripts","author":"Bancel","year":"2018"},{"key":"10.1016\/j.ijbiomac.2026.150466_bb0895","series-title":"Ion Exchange Purification of mRNA","author":"Issa","year":"2020"},{"key":"10.1016\/j.ijbiomac.2026.150466_bb0900","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.omtn.2019.02.018","article-title":"A facile method for the removal of dsRNA contaminant from in vitro-transcribed mRNA","volume":"15","author":"Baiersd\u00f6rfer","year":"2019","journal-title":"ol. Ther. Nucleic Acids"},{"issue":"1","key":"10.1016\/j.ijbiomac.2026.150466_bb0905","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1038\/s41541-022-00447-3","article-title":"Pandemic-response adenoviral vector and RNA vaccine manufacturing","volume":"7","author":"Kis","year":"2022","journal-title":"NPJ Vaccines"},{"key":"10.1016\/j.ijbiomac.2026.150466_bb0910","doi-asserted-by":"crossref","DOI":"10.1016\/j.seppur.2025.132179","article-title":"Vibration-assisted ultrafiltration dramatically improves mRNA purification","volume":"363","author":"Behboudi","year":"2025","journal-title":"Sep. Purif. Technol."},{"issue":"7","key":"10.1016\/j.ijbiomac.2026.150466_bb0915","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.3390\/molecules30071629","article-title":"Current analytical strategies for mRNA-based therapeutics","volume":"30","author":"Camperi","year":"2025","journal-title":"Molecules"},{"key":"10.1016\/j.ijbiomac.2026.150466_bb0920","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2022.114928","article-title":"Analysis of therapeutic nucleic acids by capillary electrophoresis","volume":"219","author":"Wei","year":"2022","journal-title":"J. Pharm. Biomed. Anal."},{"issue":"44","key":"10.1016\/j.ijbiomac.2026.150466_bb0925","first-page":"17789","article-title":"Exploring the impact of in vitro-transcribed mRNA impurities on cellular responses","volume":"96","author":"Camperi","year":"2024"},{"issue":"1","key":"10.1016\/j.ijbiomac.2026.150466_bb0930","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/0003-2697(87)90021-2","article-title":"Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction","volume":"162","author":"Chomczynski","year":"1987","journal-title":"Anal. Biochem."},{"issue":"6","key":"10.1016\/j.ijbiomac.2026.150466_bb0935","doi-asserted-by":"crossref","DOI":"10.1101\/pdb.prot5439","article-title":"Purification of RNA using TRIzol (TRI reagent)","volume":"2010","author":"Rio","year":"2010","journal-title":"Cold Spring Harb Protoc"},{"key":"10.1016\/j.ijbiomac.2026.150466_bb0940","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.ab.2015.03.028","article-title":"A phenol-free method for isolation of microRNA from biological fluids","volume":"479","author":"Zaporozhchenko","year":"2015","journal-title":"Anal. Biochem."},{"issue":"3","key":"10.1016\/j.ijbiomac.2026.150466_bb0945","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1128\/jcm.28.3.495-503.1990","article-title":"Rapid and simple method for purification of nucleic acids","volume":"28","author":"Boom","year":"1990","journal-title":"J. Clin. Microbiol."},{"issue":"10","key":"10.1016\/j.ijbiomac.2026.150466_bb0950","doi-asserted-by":"crossref","DOI":"10.1101\/pdb.prot101733","article-title":"Isolation of poly(A)(+) messenger RNA using magnetic oligo(dT) beads","volume":"2019","author":"Green","year":"2019","journal-title":"Cold Spring Harb Protoc"},{"issue":"21","key":"10.1016\/j.ijbiomac.2026.150466_bb0955","doi-asserted-by":"crossref","first-page":"4543","DOI":"10.1093\/nar\/22.21.4543","article-title":"DNA purification and isolation using a solid-phase","volume":"22","author":"Hawkins","year":"1994","journal-title":"Nucleic Acids Res."},{"issue":"11","key":"10.1016\/j.ijbiomac.2026.150466_bb0960","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a032276","article-title":"Principles and practices of hybridization capture experiments to study long noncoding RNAs that act on chromatin","volume":"11","author":"Simon","year":"2019","journal-title":"Cold Spring Harb. Perspect. Biol."},{"issue":"14","key":"10.1016\/j.ijbiomac.2026.150466_bb0965","doi-asserted-by":"crossref","first-page":"3239","DOI":"10.1007\/s00216-018-0943-8","article-title":"A guide to large-scale RNA sample preparation","volume":"410","author":"Baronti","year":"2018","journal-title":"Anal. Bioanal. Chem."},{"key":"10.1016\/j.ijbiomac.2026.150466_bb0970","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.copbio.2013.08.013","article-title":"Microfluidics for biological measurements with single-molecule resolution","volume":"25","author":"Streets","year":"2014","journal-title":"Curr. Opin. Biotechnol."},{"issue":"8","key":"10.1016\/j.ijbiomac.2026.150466_bb0975","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1038\/nbt718","article-title":"High-throughput SELEX SAGE method for quantitative modeling of transcription-factor binding sites","volume":"20","author":"Roulet","year":"2002","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ijbiomac.2026.150466_bb0980","first-page":"1","article-title":"A review on role of artificial intelligence (AI) in the paradigm shift of pharmaceutical sciences","volume":"2023","author":"Satyavijay","year":"2023","journal-title":"Nano Biomed. Eng."},{"issue":"20","key":"10.1016\/j.ijbiomac.2026.150466_bb0985","doi-asserted-by":"crossref","first-page":"3427","DOI":"10.1093\/bioinformatics\/bty364","article-title":"Predicting RNA\u2013protein binding sites and motifs through combining local and global deep convolutional neural networks","volume":"34","author":"Pan","year":"2018","journal-title":"Bioinformatics"},{"key":"10.1016\/j.ijbiomac.2026.150466_bb0990","doi-asserted-by":"crossref","first-page":"6795","DOI":"10.55522\/jmpas.V13I5.6689","article-title":"Application of artificial intelligence (AI) as a process analytical technology (PAT) tool in healthcare industry","volume":"13","author":"Swami","year":"2024","journal-title":"J. Med. Pharm. Allied Sci."},{"key":"10.1016\/j.ijbiomac.2026.150466_bb0995","author":"Food and D. Administration"},{"key":"10.1016\/j.ijbiomac.2026.150466_bb1000","doi-asserted-by":"crossref","DOI":"10.1016\/j.chroma.2025.465746","article-title":"Improved workflow for constructing machine learning models: predicting retention times and peak widths in oligonucleotide separation","volume":"1747","author":"Samuelsson","year":"2025","journal-title":"J. Chromatogr. A"},{"issue":"8","key":"10.1016\/j.ijbiomac.2026.150466_bb1005","article-title":"Integrating artificial intelligence in analytical chemistry: enhancing spectroscopic analysis and predictive modelling","volume":"10","author":"Musa","year":"2025","journal-title":"ASP J."},{"issue":"2","key":"10.1016\/j.ijbiomac.2026.150466_bb1010","first-page":"188","article-title":"Ai-driven predictive analytics for drug stability studies: review article","volume":"2","year":"2024","journal-title":"J. Pharma Insight Res."},{"issue":"1","key":"10.1016\/j.ijbiomac.2026.150466_bb1015","doi-asserted-by":"crossref","first-page":"5659","DOI":"10.1038\/s41467-024-50093-7","article-title":"Reformulating lipid nanoparticles for organ-targeted mRNA accumulation and translation","volume":"15","author":"Su","year":"2024","journal-title":"Nat. Commun."},{"issue":"3","key":"10.1016\/j.ijbiomac.2026.150466_bb1020","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1038\/s41565-023-01548-3","article-title":"Combinatorial development of nebulized mRNA delivery formulations for the lungs","volume":"19","author":"Jiang","year":"2024","journal-title":"Nat. Nanotechnol."},{"issue":"1","key":"10.1016\/j.ijbiomac.2026.150466_bb1025","doi-asserted-by":"crossref","first-page":"10804","DOI":"10.1038\/s41467-024-55072-6","article-title":"Artificial intelligence-driven rational design of ionizable lipids for mRNA delivery","volume":"15","author":"Wang","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ijbiomac.2026.150466_bb1030","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2024.115446","article-title":"Breaking the final barrier: evolution of cationic and ionizable lipid structure in lipid nanoparticles to escape the endosome","volume":"214","author":"Mrksich","year":"2024","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"4","key":"10.1016\/j.ijbiomac.2026.150466_bb1035","doi-asserted-by":"crossref","first-page":"4039","DOI":"10.1021\/acsnano.4c11858","article-title":"Emerging delivery systems for enabling precision nucleic acid therapeutics","volume":"19","author":"Bian","year":"2025","journal-title":"ACS Nano"},{"key":"10.1016\/j.ijbiomac.2026.150466_bb1040","series-title":"Pharmaceutical Insights Into Improving Oligonucleotide Delivery and Efficacy","author":"Saher","year":"2021"},{"issue":"1","key":"10.1016\/j.ijbiomac.2026.150466_bb1045","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/s41591-018-0300-7","article-title":"High-performance medicine: the convergence of human and artificial intelligence","volume":"25","author":"Topol","year":"2019","journal-title":"Nat. Med."},{"key":"10.1016\/j.ijbiomac.2026.150466_bb1050","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.ijms.2012.09.012","article-title":"Comparison of accurate mass LC\u2013MS and MRM LC\u2013MS\/MS for the quantification of a therapeutic small interfering RNA","volume":"345-347","author":"Wheller","year":"2013","journal-title":"Int. J. Mass Spectrom."},{"issue":"22","key":"10.1016\/j.ijbiomac.2026.150466_bb1055","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1002\/rcm.8516","article-title":"Assay determination by mass spectrometry for oligonucleotide therapeutics","volume":"33","author":"Madsen","year":"2019","journal-title":"Rapid Commun. Mass Spectrom."},{"key":"10.1016\/j.ijbiomac.2026.150466_bb1060","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.omtn.2019.07.006","article-title":"\u201cmetabolite profiling of the antisense oligonucleotide Eluforsen using liquid chromatography-mass spectrometry,\u201d (in eng)","volume":"17","author":"Kim","year":"2019","journal-title":"Mol Ther Nucleic Acids"},{"issue":"21","key":"10.1016\/j.ijbiomac.2026.150466_bb1065","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.4155\/bio-2019-0137","article-title":"Oligonucleotide quantification and metabolite profiling by high-resolution and accurate mass spectrometry","volume":"11","author":"Liu","year":"2019","journal-title":"Bioanalysis"},{"issue":"21","key":"10.1016\/j.ijbiomac.2026.150466_bb1070","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.4155\/bio-2019-0118","article-title":"Discovery of a novel deaminated metabolite of a single-stranded oligonucleotide in vivo by mass spectrometry","volume":"11","author":"Li","year":"2019","journal-title":"Bioanalysis"},{"issue":"21","key":"10.1016\/j.ijbiomac.2026.150466_bb1075","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.4155\/bio-2019-0134","article-title":"LC-TOF-MS methods to quantify siRNAs and major metabolite in plasma, urine and tissues","volume":"11","author":"Ramanathan","year":"2019","journal-title":"Bioanalysis"},{"issue":"1","key":"10.1016\/j.ijbiomac.2026.150466_bb1080","doi-asserted-by":"crossref","first-page":"3566","DOI":"10.1038\/s41598-019-40187-4","article-title":"Application of locked nucleic acid oligonucleotides for siRNA preclinical bioanalytics","volume":"9","author":"Thayer","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ijbiomac.2026.150466_bb1085","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.chroma.2018.11.029","article-title":"Direct identification of microribonucleic acid miR-451 from plasma using liquid chromatography mass spectrometry","volume":"1584","author":"Basiri","year":"2019","journal-title":"J. Chromatogr. A"},{"issue":"9","key":"10.1016\/j.ijbiomac.2026.150466_bb1090","doi-asserted-by":"crossref","first-page":"589","DOI":"10.4155\/bio-2022-0015","article-title":"Validation and application of hybridization liquid chromatography-tandem mass spectrometry methods for quantitative bioanalysis of antisense oligonucleotides","volume":"14","author":"Li","year":"2022","journal-title":"Bioanalysis"},{"key":"10.1016\/j.ijbiomac.2026.150466_bb1095","doi-asserted-by":"crossref","DOI":"10.1016\/j.talanta.2023.125173","article-title":"Improvement of serum sample preparation and chromatographic analysis of nusinersen used for the treatment of spinal muscular atrophy","volume":"267","author":"Studzi\u0144ska","year":"2024","journal-title":"Talanta"},{"issue":"5","key":"10.1016\/j.ijbiomac.2026.150466_bb1100","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1016\/j.xphs.2023.01.007","article-title":"Characterization of BNT162b2 mRNA to evaluate risk of off-target antigen translation","volume":"112","author":"Patel","year":"2023","journal-title":"J. Pharm. Sci."},{"issue":"7","key":"10.1016\/j.ijbiomac.2026.150466_bb1105","doi-asserted-by":"crossref","DOI":"10.3390\/chemosensors12070120","article-title":"Study on the characterization and degradation pattern of circular RNA vaccines using an HPLC method","volume":"12","author":"Cheng","year":"2024","journal-title":"Chemosensors"},{"key":"10.1016\/j.ijbiomac.2026.150466_bb1110","doi-asserted-by":"crossref","first-page":"3091","DOI":"10.1021\/acs.analchem.4c06296","article-title":"High-throughput quantification and characterization of dual payload mRNA\/LNP cargo via deformulating size exclusion and ion pairing reversed phase assays","volume":"97","author":"Imio\u0142ek","year":"2025","journal-title":"Anal. Chem."},{"key":"10.1016\/j.ijbiomac.2026.150466_bb1115","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2025.116695","article-title":"DNAzyme approach for simultaneous mRNA cap and poly(A) tail length analysis: a one-step method to multiple quality attributes","volume":"257","author":"Wang","year":"2025","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.ijbiomac.2026.150466_bb1120","doi-asserted-by":"crossref","DOI":"10.1016\/j.chroma.2024.464756","article-title":"Evaluation of size-exclusion chromatography, multi-angle light scattering detection and mass photometry for the characterization of mRNA","volume":"1719","author":"De Vos","year":"2024","journal-title":"J. Chromatogr. A"},{"issue":"9\u201310","key":"10.1016\/j.ijbiomac.2026.150466_bb1125","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1002\/elps.202100272","article-title":"Development of a microchip capillary electrophoresis method for determination of the purity and integrity of mRNA in lipid nanoparticle vaccines","volume":"43","author":"Raffaele","year":"2022","journal-title":"Electrophoresis"},{"key":"10.1016\/j.ijbiomac.2026.150466_bb1130","doi-asserted-by":"crossref","first-page":"115692","DOI":"10.1016\/j.jpba.2023.115692","article-title":"A single-nucleotide resolution capillary gel electrophoresis workflow for poly(a) tail characterization in the development of mRNA therapeutics and vaccines","volume":"236","author":"Di Grandi","year":"2023","journal-title":"J. Pharm. Biomed. Anal."}],"container-title":["International Journal of Biological Macromolecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0141813026003922?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0141813026003922?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T17:18:07Z","timestamp":1770052687000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0141813026003922"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":226,"alternative-id":["S0141813026003922"],"URL":"https:\/\/doi.org\/10.1016\/j.ijbiomac.2026.150466","relation":{},"ISSN":["0141-8130"],"issn-type":[{"value":"0141-8130","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recent advances in the analysis of the evolutionary RNA based therapeutics; a review","name":"articletitle","label":"Article Title"},{"value":"International Journal of Biological Macromolecules","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijbiomac.2026.150466","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"150466"}}